This publication strengthens BRIUMVI's clinical profile for early-use high-efficacy therapy, which could support formulary positioning and physician adoption. Monitor upcoming quarterly earnings for prescription trends and any label expansion updates. The data is incremental — not a binary catalyst — so expect modest positive sentiment rather than a major re-rating.
Price Chart
Executive Summary
TG Therapeutics published a post-hoc pooled analysis of Phase 3 ULTIMATE I/II data in Frontiers in Immunology, showing BRIUMVI (ublituximab) reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve RMS patients, with 82.7% achieving NEDA-3 vs. 23.1% for teriflunomide. This is a positive clinical data publication reinforcing BRIUMVI's efficacy in early-stage patients, but it is not a new regulatory event or commercial catalyst — it adds to the existing evidence base without changing the approved label or near-term revenue trajectory.
Key Facts
- BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients (0.081 vs. 0.188; p<0.001)
- In treatment-naïve patients treated within 3 years of symptom onset, ARR reduction was 61.0% (0.130 vs. 0.334; p=0.004)
- 2-fold greater confirmed disability improvement (CDI) in treatment-naïve patients (10.7% vs. 5.3%; p=0.010); 4-fold greater CDI in early-treated patients (14.4% vs. 3.6%; p=0.002)
- Ublituximab reduced gadolinium-enhancing T1 lesions by 96.1% and new/enlarging T2 lesions by 90.6% vs. teriflunomide (p<0.001 for both)
- 82.7% of treatment-naïve ublituximab patients achieved NEDA-3 vs. 23.1% for teriflunomide (3.6-fold higher; p<0.001)
- Data published in Frontiers in Immunology, a peer-reviewed journal
Financial Impact
No new financial figures provided; publication supports BRIUMVI's clinical differentiation, which may support continued market share growth in the ~$20B+ RMS market, but no revenue or guidance changes were announced.
Risk Factors
- No new regulatory or commercial catalyst — data is a post-hoc analysis, not a prospective trial
- BRIUMVI faces competition from established high-efficacy therapies (Ocrevus, Kesimpta, Tysabri) with longer track records
- Forward-looking statements caution that prescription trends and revenue targets may not be sustained
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304240 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 12w ago | 8-K | $46.17 | awaiting T+60 | — | $56.11 (+21.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $49.52 $55.74 | ▲ +12.56% | ▲ +9.30% | $56.11 (+13.31%) |
Jun 3, 2026 20w ago | 8-K | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $56.11 (+39.89%) |
Jun 3, 2026 20w ago | Press Release | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $56.11 (+39.89%) |
Jun 1, 2026 21w ago | Press Release | $37.41 $55.42 | ▲ +48.14% | ▲ +46.91% | $56.11 (+49.99%) |
May 27, 2026 21w ago | 8-K | $38.82 $54.27 | ▲ +39.80% | ▲ +38.06% | $56.11 (+44.54%) |
May 6, 2026 24w ago | 8-K | $41.97 $52.03 | ▲ +23.97% | ▲ +21.91% | $56.11 (+33.69%) |
Apr 30, 2026 25w ago | Press Release | $33.78 $55.75 | ▲ +65.04% | ▲ +61.93% | $56.11 (+66.10%) |
Apr 22, 2026 26w ago | Press Release | $38.31 $54.87 | ▲ +43.23% | ▲ +38.45% | $56.11 (+46.46%) |
Apr 15, 2026 27w ago | Press Release | $34.60 $57.12 | ▲ +65.09% | ▲ +56.95% | $56.11 (+62.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers